Hovione and Firstgene Life Sciences have announced a strategic collaboration to advance Hovione’s proprietary virus-like particle drug delivery platform for the targeted treatment of Hepatocellular Carcinoma (HCC), a therapeutic indication developed by Firstgene.  Under the terms of the collaboration, Hovione will grant Firstgene an exclusive license to its proprietary novel targeted adeno-associated virus (AAV)-like particle […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!